VPS45 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS45 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS4A Human Pre-designed siRNA Set A contains three designed siRNAs for VPS4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS4B Human Pre-designed siRNA Set A contains three designed siRNAs for VPS4B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS50 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS50 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS51 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS51 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS52 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS52 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS53 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS53 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS54 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS54 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS72 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS72 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS8 Human Pre-designed siRNA Set A contains three designed siRNAs for VPS8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for VRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for VRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for VRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VRTN Human Pre-designed siRNA Set A contains three designed siRNAs for VRTN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIG1 Human Pre-designed siRNA Set A contains three designed siRNAs for VSIG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIG10L Human Pre-designed siRNA Set A contains three designed siRNAs for VSIG10L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIG2 Human Pre-designed siRNA Set A contains three designed siRNAs for VSIG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIG4 Human Pre-designed siRNA Set A contains three designed siRNAs for VSIG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIG8 Human Pre-designed siRNA Set A contains three designed siRNAs for VSIG8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSIR Human Pre-designed siRNA Set A contains three designed siRNAs for VSIR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSNL1 Human Pre-designed siRNA Set A contains three designed siRNAs for VSNL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSTM1 Human Pre-designed siRNA Set A contains three designed siRNAs for VSTM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSTM2A Human Pre-designed siRNA Set A contains three designed siRNAs for VSTM2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSTM2B Human Pre-designed siRNA Set A contains three designed siRNAs for VSTM2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSTM2L Human Pre-designed siRNA Set A contains three designed siRNAs for VSTM2L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSTM4 Human Pre-designed siRNA Set A contains three designed siRNAs for VSTM4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSW1198 is an inhibitor for geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 45 nM. VSW1198 reveals antitumor activity in myeloma- and prostate cancer with liver toxicity[1].

VSX1 Human Pre-designed siRNA Set A contains three designed siRNAs for VSX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VSX2 Human Pre-designed siRNA Set A contains three designed siRNAs for VSX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VTA1 Human Pre-designed siRNA Set A contains three designed siRNAs for VTA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VTCN1 Human Pre-designed siRNA Set A contains three designed siRNAs for VTCN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VTI1A Human Pre-designed siRNA Set A contains three designed siRNAs for VTI1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VTI1B Human Pre-designed siRNA Set A contains three designed siRNAs for VTI1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VTN Human Pre-designed siRNA Set A contains three designed siRNAs for VTN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VU0542270 is a selective vascular Kir6.1/SUR2B KATP channel inhibitor with a IC50 value of 100 nM. VU0542270 can be used in cardiovascular disease research[1].

Vutrisiran sodium is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research[1].

Vutrisiran sodium is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research[1].

Vutrisiran sodium is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research[1].

VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers[1].

VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers[1].

VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers[1].

VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers[1].

VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers[1].

VWA1 Human Pre-designed siRNA Set A contains three designed siRNAs for VWA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VWA2 Human Pre-designed siRNA Set A contains three designed siRNAs for VWA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VWA3B Human Pre-designed siRNA Set A contains three designed siRNAs for VWA3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VWA5A Human Pre-designed siRNA Set A contains three designed siRNAs for VWA5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VWA5B2 Human Pre-designed siRNA Set A contains three designed siRNAs for VWA5B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VWA7 Human Pre-designed siRNA Set A contains three designed siRNAs for VWA7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.